An analytical result describes the sample that reached the instrument. Whether it also represents a production lot, a shipment or a seller's entire catalog is a separate question. Sample provenance is the documented path connecting those levels.

FDA's quality-testing program uses different tests to investigate different drug-quality questions, including identity, assay, impurities and other product characteristics. The program demonstrates the importance of matching the investigation to the question rather than treating testing as one universal event. FDA drug quality sampling and testing program

Start with the sampling question

For a research purchase, ask who selected the sample, where it was taken and how it was identified. Was it drawn before or after a material was divided into smaller containers? Were multiple containers involved? Was the selection representative of the material under consideration? These questions can be recorded without requesting confidential manufacturing details unrelated to the purchase.

A sample supplied by a seller is not automatically invalid. It simply has a different evidentiary scope from a sample selected independently from a delivered shipment. Likewise, a customer-submitted sample can be compromised by undocumented storage or handling before analysis.

Preserve the chain of evidence

A useful file links the purchase record, container identifier, submission record and report. If any step is missing, describe the consequence. For example, the laboratory result may be authentic while the link to the delivered lot remains uncertain.

For critical experiments, the laboratory's quality or procurement lead should decide what additional evidence is proportionate to the risk. The decision may differ for exploratory screening and a study intended to support a consequential claim.

AXON's focus is transparent scope: state exactly which sample was tested and what broader inference is justified. Avoid extending a single favorable result into a permanent judgment about a company or all future batches.